Novel class of PI3Kδ inhibitors shows efficacy in multiple sclerosis models
July 9, 2024
Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder in need of new treatment options. Inhibition of the phosphoinositide 3-kinase δ (PI3Kδ) pathway has shown efficacy in animals with experimental encephalomyelitis (EAE), a model of MS.